Ofichem acquires Uppsala site from Meribel Pharma Solutions
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.
List view / Grid view
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
The landmark regulation establishes a future where highly personalised treatments are part of routine care, says MHRA’s Chief Executive.
While a focus on accelerating access for innovative medicines has been welcomed, industry representatives caution that current system infrastructure could hinder the plans proposed by the UK Government.
Following their recent LinkedIn Live, Hexagon’s Adam Cross, Industry Director for Pharma and Life Sciences, reveals the state of data in pharmaceutical manufacturing, the opportunities available and how companies can ensure success and sustainable outcomes in their digitalisation journey.
The expanded agreement between ViiV Healthcare and Medicines Patent Pool (MPP) provides a more patient-centric treatment approach for HIV patients worldwide.
After their recent webinar, European Pharmaceutical Review’s Head of Content Ian Betteridge spoke with the team at Adragos Pharma to discuss the role of a CDMO and their importance in the fill and finish sector.
While the pharmaceutical market is expected to witness strong pricing competition, there is also significant opportunity for biotech companies, research says.
The new investment will help Sandoz to expand its European biosimilar manufacturing capacity and ensure reliable and sustainable supply in the region.
2 July 2025 | By MasterControl
This webinar explores innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.
Cell therapy expert Lindsay Davies, PhD, FHEA, discusses the key considerations for moving the needle to broader adoption of CGTs in Europe.
27 June 2025 | By Thermo Fisher Scientific
This webinar will explore how lipid formulations in softgels can enhance drug absorption and bioavailability.
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs).
This in-depth focus features articles on biosimilars and biomanufacturing in Europe, the potential of plant tissue-based bioproduction and utilising digital twins for optimisation of bioprocesses.